The effect of LMWH (Nadroparin) on tumor progression.

Article Details

Citation

Nagy Z, Turcsik V, Blasko G

The effect of LMWH (Nadroparin) on tumor progression.

Pathol Oncol Res. 2009 Dec;15(4):689-92. doi: 10.1007/s12253-009-9204-7.

PubMed ID
19757196 [ View in PubMed
]
Abstract

Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
NadroparinMyc proto-oncogene proteinProteinHumans
Unknown
Inhibitor
Details
NadroparinProto-oncogene c-FosProteinHumans
Unknown
Inhibitor
Details